Mirvetuximab soravtansine
Mirvetuximab soravtansine (Elahere) is the first ADC for ovarian cancer, for tumours with high folate receptor alpha.
Accelerated approval 2022, full approval 2024 after MIRASOL showed an OS benefit (16.5 vs 12.7 months) in FRα-high platinum-resistant ovarian cancer. Ocular toxicity (keratopathy) requires eye exams. Combination and earlier-line trials ongoing.
1.Antibody binds Folate receptor alpha on the tumour cell surface
- Route
- IV infusion
- Schedule
- 6 mg/kg adjusted ideal body weight every 3 weeks
- Dose modifications
- Hold for grade 2 keratopathy or blurred vision until grade ≤1; discontinue for grade 4 ocular events
- Monitoring
- Ophthalmic exam at baseline and every other cycle for 8 cycles; prophylactic steroid and lubricating eye drops
Source: US prescribing information (DailyMed). Doses are for orientation; the current label governs.
- Medicare
- Part B (clinician-administered)
Given by infusion or injection in a clinic or hospital outpatient department, so it is a Part B drug: Medicare pays 80% after the Part B deductible and the patient owes 20% coinsurance, uncapped in Original Medicare unless a Medigap policy applies.
- Commercial insurance
- covered with prior authorisation
Covered under the medical benefit with prior authorisation confirming diagnosis, biomarker status and line of therapy; site-of-care policies may steer infusions away from hospital outpatient departments. FRα-positive status by the approved IHC test required.
- Assistance programmes
- myAbbVie Assist
- PAN Foundation — Disease-specific co-pay and premium funds; open and closed funds change monthly.
- HealthWell Foundation
- CancerCare Co-Payment Assistance Foundation
- Patient Advocate Foundation Co-Pay Relief
20% Part B coinsurance on a high-cost infusion adds up quickly: Medigap Plan G or N, Medicare Advantage maximum out-of-pocket, Medicaid dual eligibility, or a charity fund are the usual buffers.
Sources: Medicare.gov: Chemotherapy · Medicare.gov: Prescription drugs (outpatient, Part B). Not medical or financial advice; verify with your plan.
- Notes
- MHRA-licensed 2025 for FRα-positive platinum-resistant ovarian cancer; NICE appraisal 2025-26. Check NICE.
Sources: NICE search: mirvetuximab soravtansine. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
Compare all products across the US, EU, UK, Japan, China and Australia →
- 14 Nov 2022ApprovalUS
Accelerated approval, FRα-high platinum-resistant ovarian cancer (SORAYA) source
- 22 Mar 2024ApprovalUS
Full approval with OS benefit (MIRASOL) source
- Nov 2024ApprovalEU
EMA approval source
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 2022 | FRα-high platinum-resistant ovarian cancer (full approval 2024) |
| Adverse event | Any grade | Grade 3+ |
|---|---|---|
| AST increased | 57% | — |
| Fatigue | 47% | — |
| Blurred vision | 45% | — |
| ALT increased | 38% | — |
| Keratopathy | 37% | — |
| Peripheral neuropathy | 37% | — |
| Abdominal pain | 34% | — |
| Dry eye | 29% | — |
| Diarrhoea | 29% | — |
| Nausea | 27% | — |
MIRASOL; all-grade rates. Rates read from the US prescribing information. Blank cells mean the figure was not sourced, not that it is zero.
| Country | Reimbursement | List price | Assistance |
|---|---|---|---|
| United States | Medicare Part B (physician-administered); commercial plans per formulary | not disclosed | elahere.com |
| United Kingdom | NICE: recommended for FRα-high platinum-resistant ovarian cancer (2025) | not disclosed | — |
List prices are manufacturer or Medicare figures where publicly disclosed; net prices after rebates are usually lower. Reimbursement changes; check the payer.
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Mirvetuximab soravtansine" OR ABSTRACT:"Mirvetuximab soravtansine" OR TITLE:"Elahere" OR ABSTRACT:"Elahere") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Mirvetuximab soravtansine, not a curated reading list.